Mean elimination half-life of 800 mg BID infused over 90 minutes
6.8 hours
Metabolism
72% of intravenous levonadifloxacin excreted as levonadifloxacin sulfate metabolite (approximately 50.3% in urine and 21.6% in faeces)
Dose adjustment in renal impaired patients
Not required
Dose adjustment in hepatic impairment
Not required
Liver safety
Very good
Cardiovascular system safety
Excellent
Gastrointestinal tolerability
Excellent
<5% of dose is excreted as unchanged levonadifloxacin suggesting minimal role of renal system in elimination of levonadifloxacin. ABSSSI: acute bacterial skin and skin structure infections; AUC: area under curve; BID: bis in die/twice a day; CAP: community-acquired pneumonia; cIAI: complicated intra-abdominal infections; Cmax: maximum mean plasma concentration; DFI: diabetic foot infections; MDR: multidrug-resistant; MRSA: methicillin-resistant Staphylococcus aureus; MSSA: methicillin-susceptible Staphylococcus aureus; QRSA: quinolone-resistant Staphylococcus aureus; RTI: respiratory tract infections; Tmax: time to reach maximum concentration; VISA: vancomycin-intermediate Staphylococcus aureus; VRSA: vancomycin-resistant Staphylococcus aureus.